Connective Tissue Diseases clinical trials at University of California Health
4 in progress, 3 open to eligible people
A Study of Experimental Ralinepag in Pulmonary Arterial Hypertension
open to eligible people ages 18 years and up
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
at UC Davis UCLA UCSD
A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH
open to eligible people ages 18 years and up
Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment
at UCSD
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
open to eligible people ages 18-80
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).
at UCLA
A Study of Experimental Ralinepag for Pulmonary Arterial Hypertension (PAH)
Sorry, accepting new patients by invitation only
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
at UC Davis UCLA UCSD
Our lead scientists for Connective Tissue Diseases research studies include Suzanne Kafaja, MD Timothy Fernandes, MD Rajan Saggar Namita Sood, MD.
Last updated: